Dr. E. Donnall Thomas pioneered the field of hematopoietic cell transplantation (HCT), reporting the first infusion of allogeneic bone marrow in 1957 [1]. In the decades that have followed, there have been innumerable advances in allogeneic HCT (allo-HCT). Although allo-HCT has been trialed and utilized for numerous disease indications, acute myeloid leukemia (AML) remains as the most frequent indication for this therapy [2,3]. Despite several new therapeutic approvals in AML, for many patients, allo-HCT serves as the only chance for cure. Significant advancements in elements of allogeneic transplantation, including improved understanding of when to proceed to transplant, enhanced methods for donor selection, more experience with alternative donor sources, novel approaches to graft-versus-host disease (GVHD) prophylaxis, and implementation of post-transplant maintenance strategies have allowed for broadened eligibility and application of this potentially curative modality.